Abrocitinib
An oral medication that works inside immune cells by blocking a signaling enzyme called JAK1, reducing the inflammatory signals that drive itching and skin inflammation in eczema. It is approved for moderate-to-severe atopic dermatitis in adults and adolescents when other treatments have not worked well enough. Patients should avoid live vaccines while taking it and should be aware of a small increased risk of serious infections, blood clots, and cardiovascular events.
Peso Molecular
323,4200 g/mol
LogP
1,70
TPSA
99,40 Ų
Regra dos 5 de Lipinski
Aprovado
Áreas Terapêuticas
Mecanismo de Ação
Stimulates the adaptive immune system to produce antigen-specific antibodies and memory cells, providing protective immunity against subsequent exposure to the pathogen.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Stimulates the adaptive immune system to produce antigen-specific antibodies and memory cells, providing protective immunity against subsequent exposure to the pathogen.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1
InChI
InChI=1S/C14H21N5O2S/c1-3-6-22(20,21)18-10-7-11(8-10)19(2)14-12-4-5-15-13(12)16-9-17-14/h4-5,9-11,18H,3,6-8H2,1-2H3,(H,15,16,17)/t10-,11+
Molecular Formula
C14H21N5O2S
HBD / HBA
2 / 6
Ligações Rotacionáveis
6
Átomos Pesados
22
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
An oral medication that works inside immune cells by blocking a signaling enzyme called JAK1, reducing the inflammatory signals that drive itching and skin inflammation in eczema. It is approved for moderate-to-severe atopic dermatitis in adults and adolescents when other treatments have not worked well enough. Patients should avoid live vaccines while taking it and should be aware of a small increased risk of serious infections, blood clots, and cardiovascular events.
Stimulates the adaptive immune system to produce antigen-specific antibodies and memory cells, providing protective immunity against subsequent exposure to the pathogen.
Yes, Abrocitinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3655081. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 78323835. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="abrocitinib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/abrocitinib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/abrocitinib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/abrocitinib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="abrocitinib"></drugfyi-drug>